Tag : PSORIATIC ARTHRITIS

In the head-to-head phase 3b BE-BOLD trial, dual IL-17A/IL-17F inhibition with bimekizumab demonstrated superior articular efficacy over risankizumab at week 16 in active psoriatic arthritis (PsA). Numerically higher joint and skin responses were maintained through week 24, with a comparable overall safety profile.
